Cargando…

No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis

The Warburg effect describes the circumstance that tumor cells preferentially use glycolysis rather than oxidative phosphorylation for energy production. It has been reported that this metabolic reconfiguration originates from a switch in the expression of alternative splice forms (PKM1 and PKM2) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bluemlein, Katharina, Grüning, Nana-Maria, Feichtinger, René G., Lehrach, Hans, Kofler, Barbara, Ralser, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248187/
https://www.ncbi.nlm.nih.gov/pubmed/21789790
_version_ 1782220211550683136
author Bluemlein, Katharina
Grüning, Nana-Maria
Feichtinger, René G.
Lehrach, Hans
Kofler, Barbara
Ralser, Markus
author_facet Bluemlein, Katharina
Grüning, Nana-Maria
Feichtinger, René G.
Lehrach, Hans
Kofler, Barbara
Ralser, Markus
author_sort Bluemlein, Katharina
collection PubMed
description The Warburg effect describes the circumstance that tumor cells preferentially use glycolysis rather than oxidative phosphorylation for energy production. It has been reported that this metabolic reconfiguration originates from a switch in the expression of alternative splice forms (PKM1 and PKM2) of the glycolytic enzyme pyruvate kinase (PK), which is also important for malignant transformation. However, analytical evidence for this assumption was still lacking. Using mass spectrometry, we performed an absolute quantification of PKM1 and PKM2 splice isoforms in 25 human malignant cancers, 6 benign oncocytomas, tissue matched controls, and several cell lines. PKM2 was the prominent isoform in all analyzed cancer samples and cell lines. However, this PKM2 dominance was not a result of a change in isoform expression, since PKM2 was also the predominant PKM isoform in matched control tissues. In unaffected kidney, lung, liver, and thyroid, PKM2 accounted for a minimum of 93% of total PKM, for 80% - 96% of PKM in colon, and 55% - 61% of PKM in bladder. Similar results were obtained for a panel of tumor and non-transformed cell lines, where PKM2 was the predominant form. Thus, our results reveal that an exchange in PKM1 to PKM2 isoform expression during cancer formation is not occurring, nor do these results support conclusions that PKM2 is specific for proliferating, and PKM1 for non-proliferating tissue.
format Online
Article
Text
id pubmed-3248187
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-32481872012-01-18 No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis Bluemlein, Katharina Grüning, Nana-Maria Feichtinger, René G. Lehrach, Hans Kofler, Barbara Ralser, Markus Oncotarget Research Papers The Warburg effect describes the circumstance that tumor cells preferentially use glycolysis rather than oxidative phosphorylation for energy production. It has been reported that this metabolic reconfiguration originates from a switch in the expression of alternative splice forms (PKM1 and PKM2) of the glycolytic enzyme pyruvate kinase (PK), which is also important for malignant transformation. However, analytical evidence for this assumption was still lacking. Using mass spectrometry, we performed an absolute quantification of PKM1 and PKM2 splice isoforms in 25 human malignant cancers, 6 benign oncocytomas, tissue matched controls, and several cell lines. PKM2 was the prominent isoform in all analyzed cancer samples and cell lines. However, this PKM2 dominance was not a result of a change in isoform expression, since PKM2 was also the predominant PKM isoform in matched control tissues. In unaffected kidney, lung, liver, and thyroid, PKM2 accounted for a minimum of 93% of total PKM, for 80% - 96% of PKM in colon, and 55% - 61% of PKM in bladder. Similar results were obtained for a panel of tumor and non-transformed cell lines, where PKM2 was the predominant form. Thus, our results reveal that an exchange in PKM1 to PKM2 isoform expression during cancer formation is not occurring, nor do these results support conclusions that PKM2 is specific for proliferating, and PKM1 for non-proliferating tissue. Impact Journals LLC 2011-05-22 /pmc/articles/PMC3248187/ /pubmed/21789790 Text en Copyright: © 2011 Bluemlein et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Papers
Bluemlein, Katharina
Grüning, Nana-Maria
Feichtinger, René G.
Lehrach, Hans
Kofler, Barbara
Ralser, Markus
No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title_full No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title_fullStr No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title_full_unstemmed No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title_short No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis
title_sort no evidence for a shift in pyruvate kinase pkm1 to pkm2 expression during tumorigenesis
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248187/
https://www.ncbi.nlm.nih.gov/pubmed/21789790
work_keys_str_mv AT bluemleinkatharina noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis
AT gruningnanamaria noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis
AT feichtingerreneg noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis
AT lehrachhans noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis
AT koflerbarbara noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis
AT ralsermarkus noevidenceforashiftinpyruvatekinasepkm1topkm2expressionduringtumorigenesis